Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2030

Conditions

Stage III Non-small Cell Lung Cancer

Interventions

DRUG

Toripalimab